Luspatercept for adults with transfusion-dependent aplastic anemia
Treatments studied
Part of Blood & lymphatic clinical trials.
This study tests a drug called luspatercept for people with a mild form of aplastic anemia who still need frequent blood transfusions. Luspatercept may help your body make more red blood cells, reducing the need for transfusions and improving your energy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You need to have been diagnosed with a type of aplastic anemia that requires regular blood transfusions but is not severe (transfusion-dependent non-severe aplastic anemia).
- A bone marrow test must show that your bone marrow is producing a certain level of red blood cell precursors (more than 15%).
- If you've already been on treatments like immunosuppressants, androgens, erythropoietin, or TPO-RA, you must have completed them without success (and if on TPO-RA, you need a 1-month break before joining).
- Your blood iron level (ferritin) must be very high (at least 1000), which is common after many transfusions.
- You need to have completed specific genetic testing (whole exome sequencing and an MDS/AA gene panel).
- You must not have severe liver, kidney, heart, or blood pressure problems, nor a large PNH clone (a related blood disorder).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of drugs to help your bone marrow make more blood cells if you have aplastic anemia and cannot have a stem cell transplant or standard immune therapy. It might improve blood counts and reduce the need for transfusions.
This study tests a drug called luspatercept to see if it can help people who have low red blood cells (anemia) after a stem cell transplant for leukemia. It may improve your energy and reduce the need for blood transfusions.
This trial tests if luspatercept can help improve red blood cell counts in people with a certain type of acute myeloid leukemia (AML) who have mild to moderate anemia after intensive chemotherapy. It is for patients with a lower-risk form of AML who have completed 1–3 cycles of high-dose consolidation therapy.
This trial tests whether a medication called luspatercept can help raise red blood cells faster after a stem cell transplant for blood cancer. It aims to reduce severe anemia and improve recovery.
This Phase 2 trial studies whether luspatercept can improve anemia in people with lower-risk myelodysplastic syndrome (MDS) who do not currently need red-blood-cell transfusions. It’s also looking to see if the benefit is similar whether or not you have ring sideroblasts.
This trial tests a drug called luspatercept to see if it can help your body make blood cells faster after a stem cell transplant. It is for people with blood cancers and moderate to severe bone marrow scarring (myelofibrosis).
Hear when a new Transfusion-dependent Non-severe Aplastic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.